Fenethylline
Identification
- Name
- Fenethylline
- Accession Number
- DB01482
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Fenethylline (DB01482)
- Weight
- Average: 341.415
Monoisotopic: 341.185175001 - Chemical Formula
- C18H23N5O2
- Synonyms
- Amfetyline
- Fenethylline
- Fenetilina
- Fenetillina
- Fenetylline
- Fenetyllinum
- External IDs
- D323
- HOMBURG-814
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
- Not Available
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbametapir The serum concentration of Fenethylline can be increased when it is combined with Abametapir. Abatacept The metabolism of Fenethylline can be increased when combined with Abatacept. Abiraterone The serum concentration of Fenethylline can be increased when it is combined with Abiraterone. Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Fenethylline. Acenocoumarol The metabolism of Fenethylline can be decreased when combined with Acenocoumarol. Acetaminophen The metabolism of Fenethylline can be decreased when combined with Acetaminophen. Acetazolamide Acetazolamide may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy. Acyclovir The metabolism of Fenethylline can be decreased when combined with Acyclovir. Adalimumab The serum concentration of Fenethylline can be decreased when it is combined with Adalimumab. Adenosine The therapeutic efficacy of Adenosine can be decreased when used in combination with Fenethylline. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Product Ingredients
Ingredient UNII CAS InChI Key Fenethylline hydrochloride YA7K8ADZ2V 1892-80-4 MVXGSLGVWBVZCA-UHFFFAOYSA-N - International/Other Brands
- Captagon (Meda)
Categories
- ATC Codes
- N06BA10 — Fenetylline
- Drug Categories
- Alkaloids
- Amines
- Central Nervous System Agents
- Central Nervous System Stimulants
- Centrally Acting Sympathomimetics
- Cytochrome P-450 CYP1A2 Substrates
- Cytochrome P-450 Substrates
- Ethylamines
- Heterocyclic Compounds, Fused-Ring
- Nervous System
- Phenethylamines
- Psychoanaleptics
- Psychostimulants, Agents Used for Adhd and Nootropics
- Purines
- Purinones
- Xanthine derivatives
- Classification
- Not classified
Chemical Identifiers
- UNII
- YZ0N7VL5R3
- CAS number
- 3736-08-1
- InChI Key
- NMCHYWGKBADVMK-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H23N5O2/c1-13(11-14-7-5-4-6-8-14)19-9-10-23-12-20-16-15(23)17(24)22(3)18(25)21(16)2/h4-8,12-13,19H,9-11H2,1-3H3
- IUPAC Name
- 1,3-dimethyl-7-{2-[(1-phenylpropan-2-yl)amino]ethyl}-2,3,6,7-tetrahydro-1H-purine-2,6-dione
- SMILES
- CC(CC1=CC=CC=C1)NCCN1C=NC2=C1C(=O)N(C)C(=O)N2C
References
- Synthesis Reference
Kohlstaedt, E. and Klingler, K.H.; U.S. Patent 3,029,239; April 10, 1962; assigned to Chemiewerke Homburg.
- General References
- Not Available
- External Links
- PubChem Compound
- 102710
- PubChem Substance
- 46505193
- ChemSpider
- 18398
- 24840
- ChEBI
- 135451
- ChEMBL
- CHEMBL2111152
- Wikipedia
- Fenethylline
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 227-229 Kohlstaedt, E. and Klingler, K.H.; U.S. Patent 3,029,239; April 10, 1962; assigned to Chemiewerke Homburg. - Predicted Properties
Property Value Source logP 1.52 ChemAxon pKa (Strongest Basic) 10.03 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 70.47 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 96.34 m3·mol-1 ChemAxon Polarizability 36.03 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9145 Caco-2 permeable - 0.6141 P-glycoprotein substrate Substrate 0.7324 P-glycoprotein inhibitor I Non-inhibitor 0.706 P-glycoprotein inhibitor II Inhibitor 0.7238 Renal organic cation transporter Non-inhibitor 0.6446 CYP450 2C9 substrate Non-substrate 0.722 CYP450 2D6 substrate Non-substrate 0.8058 CYP450 3A4 substrate Substrate 0.6524 CYP450 1A2 substrate Non-inhibitor 0.7432 CYP450 2C9 inhibitor Non-inhibitor 0.7196 CYP450 2D6 inhibitor Non-inhibitor 0.7984 CYP450 2C19 inhibitor Non-inhibitor 0.6107 CYP450 3A4 inhibitor Inhibitor 0.6417 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.624 Ames test Non AMES toxic 0.5 Carcinogenicity Non-carcinogens 0.788 Biodegradation Not ready biodegradable 0.9918 Rat acute toxicity 3.1898 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.5 hERG inhibition (predictor II) Inhibitor 0.6707
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- Curator comments
- This enzyme listing is based on pharmacokinetic data for methylxanthines as a drug class. Methylxanthines are metabolized by CYP1A2. This drug is a methylxanthine and is therefore assumed to be metabolized by this enzyme.
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Buters JT, Tang BK, Pineau T, Gelboin HV, Kimura S, Gonzalez FJ: Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2. Pharmacogenetics. 1996 Aug;6(4):291-6. [PubMed:8873215]
- Hakooz NM: Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities. Curr Drug Metab. 2009 May;10(4):329-38. [PubMed:19519341]
- Rasmussen BB, Brosen K: Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit. 1996 Jun;18(3):254-62. [PubMed:8738764]
- Thorn CF, Aklillu E, McDonagh EM, Klein TE, Altman RB: PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95. doi: 10.1097/FPC.0b013e3283505d5e. [PubMed:22293536]
- Theophylline metabolic pathway [Link]
- CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine [File]
Drug created on July 31, 2007 13:09 / Updated on June 12, 2020 16:51